Novartis’s Gilenya® got Approved by FDA for Pediatric Relapsing Multiple Sclerosis By: Novartis News Novartis announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis (RMS), making [..]
FDA Grants Priority Review to Genentech’s Cancer Immunotherapy Tecentriq By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination [..]
First-in-World Robot-Assisted Spinal Surgery By: University of Pennsylvania School of Medicine Noah Pernikoff is back to his life in New York City after becoming the first patient in the world to undergo a complex three-part, robotic-assisted surgery. The robotic arms made it possible for the multidisciplinary team at Penn to successfully [..]
Could Robots be Counsellors? Early Research Shows Positive User Experience By: University of Plymouth News New research has shown for the first time that a social robot can deliver a ‘helpful’ and ‘enjoyable’ motivational interview (MI) – a counselling technique designed to support behaviour change. Many participants in the University of [..]
Tafinlar® + Mekinist® of Novartis Receives FDA Approval for the Treatment of BRAF V600-Mutant Melanoma By: Novartis News Novartis announced that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as [..]
Novartis Receives Second FDA Approval for Kymriah® to Treat B-cell Lymphoma By: Novartis News Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication – the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two [..]
Copyright © 2025 | WordPress Theme by MH Themes